HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jason Gong Selected Research

fesoterodine

1/2014Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
6/2012Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
5/2011Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial.
5/2011Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder.
2/2011Early onset of fesoterodine efficacy in subjects with overactive bladder.
2/2011Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study.
1/2010Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
1/2010Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jason Gong Research Topics

Disease

7Overactive Urinary Bladder (Overactive Bladder)
06/2012 - 01/2010
5Urinary Incontinence
01/2014 - 01/2010
4Constipation
06/2012 - 01/2010
3Nausea
04/2007 - 07/2006
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2022 - 10/2021
2Sleep Initiation and Maintenance Disorders (Insomnia)
04/2007 - 07/2006
1Chronic Kidney Failure (Chronic Renal Failure)
03/2022
1Urolithiasis
01/2018
1Urinary Retention
06/2012
1Lower Urinary Tract Symptoms
06/2012
1Dysuria
06/2012
1Cataract (Cataracts)
04/2007
1Substance Withdrawal Syndrome (Withdrawal Symptoms)
07/2006
1Neoplasms (Cancer)
06/2006

Drug/Important Bio-Agent (IBA)

8fesoterodineFDA Link
01/2014 - 01/2010
3Tolterodine Tartrate (Detrol)FDA Link
05/2011 - 01/2010
3Varenicline (Chantix)FDA Link
04/2007 - 07/2006
2lorlatinibIBA
03/2022 - 10/2021
2Anaplastic Lymphoma KinaseIBA
03/2022 - 10/2021
2Muscarinic AntagonistsIBA
01/2014 - 06/2012
1Tyrosine Kinase InhibitorsIBA
10/2021
1nicotinic receptor alpha4beta2IBA
07/2006
1NicotineFDA Link
07/2006
1Pharmaceutical PreparationsIBA
07/2006
1Bupropion (Wellbutrin)FDA LinkGeneric
07/2006
1ElementsIBA
06/2006

Therapy/Procedure

1Lasers (Laser)
01/2018
1Lithotripsy (Extracorporeal Shockwave Lithotripsy)
01/2018
1Laser Lithotripsy
01/2018